AstraZeneca sues FDA with 'poison pill' attack; claims Seroquel warnings are its IP
This article was originally published in Scrip
In a case that might start to explain why it can take until near the end of a drug's patented lifetime to define and recognise some of its adverse effects, AstraZeneca has filed a lawsuit against the US FDA in a last-ditch attempt to keep generic Seroquel (quetiapine fumarate) off the market until December. The pharma company is hoping to overturn the agency's recent decision not to delay approval of generic versions of its best-selling anti-depressant.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.